INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Reata Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: RETA) - Insurance News

NEW YORK, May 26, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Reata Pharmaceuticals, Inc.:

On May 10, 2023, Reata issued a press release announcing its financial results for the first quarter of 2023. Among other items, Reata announced its decision to discontinue studies for its kidney disease candidate bardoxolone, which the Company had previously advanced as one of its lead assets in partnership with Blackstone Life Sciences and Kyoma Kirin. On this news, Reata's stock price fell $14.99 per share or 14.23%, to close at $90.38 per share on May 10, 2023.

Due to the forgoing, The Gross Law Firm is investigating potential securities fraud claims on behalf of certain Reata investors. If you incurred a loss on your RETA investment, please contact us using the link below to discuss your rights.

https://securitiesclasslaw.com/securities/reata-loss-submission-form/?wire=

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903